“Designer solvent hits hospital superbug” refers to a 2012 laboratory finding: researchers identified a chiral imidazolium salt with preliminary activity against MRSA, or methicillin-resistant Staphylococcus aureus. It was a screening result, not a treatment tested in patients. The peer-reviewed study and the Royal Society of Chemistry’s contemporaneous summary describe the chemical series and its early results.
What was the “designer solvent”?
The phrase describes an ionic liquid in the imidazolium salt family. Ionic liquids are salts that are liquid at relatively low temperatures; in this study, researchers made chiral imidazolium salts and screened them for biological effects. “Designer” refers to tailoring the compounds’ chemical structures, not to a consumer product or a ready-to-use medicine.
As an Amazon Associate I earn from qualifying purchases.
Deborah Coleman, Marcel Špulák, M. Teresa Garcia and Nicholas Gathergood reported the work in Green Chemistry. The paper was first published on 15 March 2012, in volume 14, pages 1350–1356. Its title characterizes the result as a “hit,” which should be understood as an early laboratory lead.
What did the researchers test and find?
The team screened a series of chiral imidazolium salts against 8 bacterial strains and 12 fungal strains, according to the Royal Society of Chemistry’s 2012 summary. The organisms included clinical pathogen strains. Most of the tested salts were reported as nontoxic to the organisms screened at IC95 greater than 2 mM; this is an assay result for those compounds, not a measure of safety in people.
#1 Best Overall
Two compounds showed high toxicity to Gram-positive bacteria, including MRSA. Both had a phenylalanine motif positioned next to the cation core. A related analogue with a phenylalanine-phenylalanine sequence was less active and did not show the same MRSA selectivity. The paper also discusses preliminary structure–activity observations involving the placement of L-phenylalanine and L-valine groups. These comparisons apply to the tested chemical series; they do not establish a general property of ionic liquids.
Why is the MRSA result not a treatment?
The reported activity came from laboratory screening. The study does not establish that the compound is effective or safe in humans, nor does it show that it can treat an infection in a patient. An in-vitro hit is a starting point for further investigation, not evidence of clinical benefit or readiness.
Rank #2
The cited study and summary do not establish whether the compound later entered clinical development, received regulatory approval, or became a marketed treatment. The result should therefore be described as a 2012 laboratory finding, not as a current MRSA therapy.
Recommended Free Tools
What did the biodegradation test show?
Two tested bromide ionic liquids containing L-phenylalanine residues achieved greater than 60% biodegradation in 28 days in the ISO 14593 CO2 Headspace test, as reported by the Royal Society of Chemistry in 2012. The authors described those particular compounds as readily biodegradable. That result does not show that ionic liquids as a class biodegrade readily or are environmentally harmless.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the study does—and does not—tell us
- It does: identify a preliminary MRSA-active compound in a specific series of synthesized chiral imidazolium salts and report structure-related differences in laboratory activity.
- It does not: demonstrate a medicine, human safety, patient benefit, regulatory approval, or a broadly applicable antibacterial effect.
- It also reports: a biodegradation result for two tested compounds under one specified assay, not an environmental assessment of the whole ionic-liquid family.
For the original details, see the Royal Society of Chemistry article and its 15 March 2012 blog summary.
Quick Recap
Best Value
- New
- Mint Condition
- Dispatch same day for order received before 12 noon
- Guaranteed packaging
- No quibbles returns
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
